The startup develops novel peptide conjugates derived from antimicrobial peptides (AMPs) to create next-generation antibody-drug conjugates (ADCs) that effectively combat antibiotic resistance. Their proprietary technology produces a new class of antibiotics with strong efficacy and a lower likelihood of inducing bacterial resistance, enhancing treatment options for patients.
Funding
$5.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional antibody-drug conjugates (ADCs) often suffer from limited internalization into target cells, resulting in suboptimal drug delivery and reduced efficacy, particularly in oncology applications. This bottleneck restricts the therapeutic potential of ADCs and can lead to cancer cell survival and drug resistance.
Solution
Lytica Therapeutics is an ADC platform company developing a novel Stapled Internalization Promoter (SIP) technology to enhance ADC internalization and efficacy. Their modular S.P.A.C.E. (Stapled Peptide Antibody Conjugate Engineering) platform enables optimization of antibody conjugates for maximum safety and efficacy. The SIP technology promotes antibody internalization, unlocking therapeutic applications for antibody drug conjugates, oligonucleotide conjugates, and degraders. Lytica's approach allows for wide linker compatibility and flexible peptide antibody ratios (PARs) from one to eight, enabling modular antibody functionalization.
Target Audience
Lytica's primary customers are biotech and pharmaceutical companies seeking to improve the internalization and efficacy of their antibody conjugates, as well as researchers in the oncology field.
Features
- Proprietary Stapled Internalization Promoter (SIP) technology to enhance antibody internalization
- Modular S.P.A.C.E. (Stapled Peptide Antibody Conjugate Engineering) platform for optimizing antibody conjugates
- Wide linker compatibility for incorporating a variety of linkers
- Flexible Peptide Antibody Ratio (PAR) allowing for ratios from one to eight
- Capability to optimize drug delivery for ADCs
- Ability to deliver oligonucleotides and alter pathogenic gene expression for AOCs
- Potential to degrade surface proteins to disrupt signaling pathways using degraders